338 related articles for article (PubMed ID: 17588628)
1. Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy.
Santen RJ; Demers L; Ohorodnik S; Settlage J; Langecker P; Blanchett D; Goss PE; Wang S
Steroids; 2007 Jul; 72(8):666-71. PubMed ID: 17588628
[TBL] [Abstract][Full Text] [Related]
2. Use of ultrasensitive recombinant cell bioassay to measure estrogen levels in women with breast cancer receiving the aromatase inhibitor, letrozole.
Klein KO; Demers LM; Santner SJ; Baron J; Cutler GB; Santen RJ
J Clin Endocrinol Metab; 1995 Sep; 80(9):2658-60. PubMed ID: 7673408
[TBL] [Abstract][Full Text] [Related]
3. Potential role of ultra-sensitive estradiol assays in estimating the risk of breast cancer and fractures.
Santen RJ; Lee JS; Wang S; Demers LM; Mauras N; Wang H; Singh R
Steroids; 2008 Dec; 73(13):1318-21. PubMed ID: 18614192
[TBL] [Abstract][Full Text] [Related]
4. Higher than expected estradiol levels in aromatase inhibitor-treated, postmenopausal breast cancer patients.
Kunovac Kallak T; Baumgart J; Stavreus Evers A; Sundström Poromaa I; Moby L; Kask K; Norjavaara E; Kushnir MM; Bergquist J; Nilsson K
Climacteric; 2012 Oct; 15(5):473-80. PubMed ID: 22324859
[TBL] [Abstract][Full Text] [Related]
5. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.
Geisler J; Helle H; Ekse D; Duong NK; Evans DB; Nordbø Y; Aas T; Lønning PE
Clin Cancer Res; 2008 Oct; 14(19):6330-5. PubMed ID: 18829517
[TBL] [Abstract][Full Text] [Related]
6. Identification of the aromatase inhibitor letrozole in urine by gas chromatography/mass spectrometry.
Mareck U; Sigmund G; Opfermann G; Geyer H; Thevis M; Schänzer W
Rapid Commun Mass Spectrom; 2005; 19(24):3689-93. PubMed ID: 16299697
[TBL] [Abstract][Full Text] [Related]
7. Development and evaluation of a reference measurement procedure for the determination of estradiol-17beta in human serum using isotope-dilution liquid chromatography-tandem mass spectrometry.
Tai SS; Welch MJ
Anal Chem; 2005 Oct; 77(19):6359-63. PubMed ID: 16194100
[TBL] [Abstract][Full Text] [Related]
8. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Dixon JM; Renshaw L; Young O; Murray J; Macaskill EJ; McHugh M; Folkerd E; Cameron DA; A'Hern RP; Dowsett M
J Clin Oncol; 2008 Apr; 26(10):1671-6. PubMed ID: 18375896
[TBL] [Abstract][Full Text] [Related]
9. Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer.
Lipton A; Leitzel K; Chaudri-Ross HA; Evans DB; Ali SM; Demers L; Hamer P; Brown-Shimer S; Pierce K; Gaur V; Carney W
J Clin Oncol; 2008 Jun; 26(16):2653-8. PubMed ID: 18443351
[TBL] [Abstract][Full Text] [Related]
10. Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate.
Lønning PE; Geisler J; Johannessen DC; Ekse D
J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):255-60. PubMed ID: 9365198
[TBL] [Abstract][Full Text] [Related]
11. Mass spectrometric and physiological validation of a sensitive, automated, direct immunoassay for serum estradiol using the Architect.
Sluss PM; Hayes FJ; Adams JM; Barnes W; Williams G; Frost S; Ramp J; Pacenti D; Lehotay DC; George S; Ramsay C; Doss RC; Crowley WF
Clin Chim Acta; 2008 Feb; 388(1-2):99-105. PubMed ID: 18023274
[TBL] [Abstract][Full Text] [Related]
12. Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels.
Hubalek M; Oberguggenberger A; Beer B; Meraner V; Sztankay M; Oberacher H; Schubert B; Wildt L; Seeber B; Giesinger J; Kemmler G; Holzner B; Sperner-Unterweger B
Clin Breast Cancer; 2014 Aug; 14(4):291-6. PubMed ID: 24468298
[TBL] [Abstract][Full Text] [Related]
13. Reproducibility of serum sex steroid assays in men by RIA and mass spectrometry.
Hsing AW; Stanczyk FZ; Bélanger A; Schroeder P; Chang L; Falk RT; Fears TR
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1004-8. PubMed ID: 17507629
[TBL] [Abstract][Full Text] [Related]
14. Plasma estrone sulfate assay in men: Comparison of radioimmunoassay, mass spectrometry coupled to gas chromatography (GC-MS), and liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Giton F; Caron P; Bérubé R; Bélanger A; Barbier O; Fiet J
Clin Chim Acta; 2010 Sep; 411(17-18):1208-13. PubMed ID: 20427015
[TBL] [Abstract][Full Text] [Related]
15. Androgen levels during adjuvant endocrine therapy in postmenopausal breast cancer patients.
Baumgart J; Nilsson K; Stavreus Evers A; Kunovac Kallak T; Kushnir MM; Bergquist J; Sundström Poromaa I
Climacteric; 2014 Feb; 17(1):48-54. PubMed ID: 23647561
[TBL] [Abstract][Full Text] [Related]
16. Aromatase inhibitors in human lung cancer therapy.
Weinberg OK; Marquez-Garban DC; Fishbein MC; Goodglick L; Garban HJ; Dubinett SM; Pietras RJ
Cancer Res; 2005 Dec; 65(24):11287-91. PubMed ID: 16357134
[TBL] [Abstract][Full Text] [Related]
17. Hydrophilic interaction liquid chromatography-tandem mass spectrometry determination of estrogen conjugates in human urine.
Qin F; Zhao YY; Sawyer MB; Li XF
Anal Chem; 2008 May; 80(9):3404-11. PubMed ID: 18348576
[TBL] [Abstract][Full Text] [Related]
18. Estrogen and tibolone metabolite levels in blood and breast tissue of postmenopausal women recently diagnosed with early-stage breast cancer and treated with tibolone or placebo for 14 days.
Kloosterboer HJ; Löfgren L; von Schoulz E; von Schoultz B; Verheul HA
Reprod Sci; 2007 Feb; 14(2):151-9. PubMed ID: 17636226
[TBL] [Abstract][Full Text] [Related]
19. Letrozole administration during the luteal phase after ovarian stimulation impacts corpus luteum function: a randomized, placebo-controlled trial.
Garcia-Velasco JA; Quea G; Piró M; Mayoral M; Ruiz M; Toribio M; Requena A
Fertil Steril; 2009 Jul; 92(1):222-5. PubMed ID: 18710719
[TBL] [Abstract][Full Text] [Related]
20. Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group.
Radlmaier A; Eickenberg HU; Fletcher MS; Fourcade RO; Reis Santos JM; van Aubel OG; Bono AV
Prostate; 1996 Oct; 29(4):199-208. PubMed ID: 8876703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
